Product Center
Marketing Application for Quadrivalent Influenza Virus Subunit Vaccine for Children Aged 6-35 Months Accepted!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-06-28
- Views:
(Summary description)On June 28, 2024, Ab&B Bio Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") submitted a marketing application for its "quadrivalent influenza virus subunit vaccine" for children aged 6-35 months, which was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China.
Marketing Application for Quadrivalent Influenza Virus Subunit Vaccine for Children Aged 6-35 Months Accepted!
(Summary description)On June 28, 2024, Ab&B Bio Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") submitted a marketing application for its "quadrivalent influenza virus subunit vaccine" for children aged 6-35 months, which was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-06-28 10:17
- Views:
On June 28, 2024, Ab&B Bio Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") submitted a marketing application for its "quadrivalent influenza virus subunit vaccine" for children aged 6-35 months, which was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China.

Source: Center for Drug Evaluation of the National Medical Products Administration
At present, the influenza virus remains one of the most important respiratory pathogens threatening public health. Seasonal influenza outbreaks or occasional cross-species transmission and pandemics of the influenza virus have significant impacts on human health and socioeconomic development. Especially for infants, the elderly, and patients with underlying cardiovascular and pulmonary diseases, infection with the influenza virus may lead to serious complications such as pneumonia, potentially resulting in severe illness or death. Currently, getting vaccinated against influenza is the most effective measure to prevent influenza infection and pandemics.
The acceptance of this marketing application for the quadrivalent influenza virus subunit vaccine for children aged 6-35 months is another significant milestone for Ab&B Bio's subunit influenza vaccine portfolio. The vaccine has completed Phase III clinical trials and met the expected endpoints. This high-quality vaccine, which combines high purity, low adverse effects, good safety, and comprehensive protection, will become China's first universally applicable quadrivalent influenza virus subunit vaccine for all age groups! It is expected to be approved for market launch in 2025! Ab&B Bio will continue to work diligently to achieve the launch of multiple products, safeguarding human life and health!
Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groups
Influenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us